On February 6, 2018, UACT and 43 other organizations sent a letter to leaders in Congress, urging them to increase patients access to generic drugs by passing the CREATES Act. When the FDA registers a brand name drug, it sometimes requires the manufacturer to submit a risk management strategy (called REMS), containing a plan for how the drug will be managed in order to ensure that the benefits to patients outweigh the potential risks of side effects or adverse outcomes. These protocols can include restrictions on how and to whom the drugs can be distributed, for example saying that a drug can only be dispensedRead More →

On December 8, 2017, UACT submitted a letter to the US, Canadian, and Mexican representatives of the NAFTA re-negotiations. Please find below the full text of the letter. A PDF version is available here. Union for Affordable Cancer Treatment 1621 Connecticut Avenue NW Suite 500 Washington, DC 20009 Tel.: 202.332.2670 www.uact.org December 8, 2017 Dear NAFTA Delegates, The Union for Affordable Cancer Treatment (UACT), created in 2014, is a union of people affected by cancer, their family members and friends, people who take care of people with cancer, health care professionals and cancer researchers committed to increasing access to effective cancer treatment and care. WeRead More →

On November 17, 2017, UACT submitted written comments the US Food and Drug Administration’s request for comments concerning, “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” The call for comments followed a public meeting hosted by the FDA in July 2017. The comments submitted by UACT call for the FDA to support three measures that would help increase access to cancer treatments and other medical technologies.  These measures include compulsory licensing as leverage for the proposed Medicare negotiation powers, the FDA to require greater transparency of R&D costs as a condition of marketing approval, and support for feasibility studies to explore businessRead More →

On November 6, 2017, UACT sent a letter to the US Congress, supporting legislation to permit the United States to negotiation prices for drugs reimbursed by the Medicare program, but also ask the Congress to include language on compulsory licensing of patents, in order to ensure that when there is a dispute over the price, the monopoly is put at risk, rather than the patient.   The letter also asks Congress to enact measures to enhance the transparency of R&D costs and drug manufacturing know-how, and under feasibility studies of delinkage. A copy of the letter is available as a PDF, here , and reads as follows: NovemberRead More →

On October 10, 2017, UACT and 22 NGOs working on cancer in South Africa, submitted comments to the South Africa on the Draft South Africa IP Policy. A PDF of the letter is available here: UACT-S.Africa-IPpolicy-10Oct2017 The text of the submission follows: October 10, 2017 The Honorable Dr. Rob Davies Minister of Trade and Industry 77 Meintjies Street Sunnyside, Pretoria, Gauteng, South Africa Re: Draft National Policy on Intellectual Property Dear Minister Davies, We write to you on behalf of the Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer, their family members and friends, people who take care of peopleRead More →